The consensus recommendation by Thomson Reuters analysts is Outperform and their mean rating for the stock is 1.60 on scale of 1-5. Analysts mean target price for Zogenix, Inc. (NASDAQ:ZGNX) is $19.80 while their …
NASDAQ
Zogenix, Inc. (NASDAQ:ZGNX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The brokerage currently has a $14.00 …
Research
Scansource (NASDAQ: SCSC) last traded at $43.50 up 8.48 percent on 459,337 total stock volume. Zogenix (NASDAQ: ZGNX) last traded at …
NASDAQ
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Zogenix Inc. (ZGNX), where a total of 1,940 contracts have traded so far, representing approximately 194,000 …
Dravet syndrome is a rare and potentially deadly form of pediatric epilepsy that currently lacks any form of FDA-approved pharmaceutical treatment. So, if approved, ZX008 would probably grab a premium pricing structure as …
The Motley Fool
Zogenix stock analysis involves checking at least a few of the important things like: Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will …
... https://zolmax.com/investing/aegis-reaffirms-buy-rating-for-zogenix-inc-zgnx/1142083.html. A number of institutional investors have recently bought and sold shares of the stock. Palo Alto Investors LLC raised its …
Aegis
Zogenix Inc. (NASDAQ:ZGNX)‘s stock had its “outperform” rating reissued by investment analysts at Leerink Swann in a report released on Tuesday. They currently have a $17.00 target price on the stock. Leerink …
Stock market analysts and brokers have recently amended their target prices on shares of Zogenix, Inc. (ZGNX). According to the latest research reports released, 3 analysts have issued a rating of “buy”, 1 analysts …
... strengths along with likely buyout speculation should propel ZGNX stock back over $6.00 for a healthy 3-bagger gain. For those reasons (and more to come in a second ZGNX article), Zogenix is my top biotech
NASDAQ